ReviewBlut1990
Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.
Review in Blut, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 50 citations in OpenAlex.
- Factors associated with transfusion requirements during treatment for acute myelogenous leukemia.Annals of hematology · 1993Trial
- Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia.Annals of hematologyTrial
- [Therapy of infections in patients with acute leukemia].Medizinische Klinik (Munich, Germany : 1983) · 1997Review
- Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.Drugs & aging · 1996Review
- Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.Journal of cancer research and clinical oncology · 1992Article
- Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.Annals of hematology · 1991Review
- [Thrombocyte transfusion: clinical aspects, follow-up and complications].Klinische Wochenschrift · 1991Review
- Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.Annals of hematology · 1991Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Among the responders, 25% can be cured by intensive and long-term chemotherapy. Since the effect of chemotherapy appears not to be limited to a special period of time, its antileukemic and curative potential could be further exploited by multiple-step chemotherapy combining double induction, intensified consolidation and long-term maintenance. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing the cure rate in AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.